ZEB1 and metastatic melanoma: Immunohistochemical analyses of a metastatic melanoma sample from the patient, from whom the ESP cells were established, revealed low ZEB1 and TWIST1 protein levels before treatment (Fig EV1C), confirming the increase in ZEB1 expression upon acquisition of resistance to vemurafenib.